Clinical trials: KRAS-mutated
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Ladarixin With Sotorasib in Advanced NSCLC - Phase II
Study record has been combined with NCT05815173. See NCT05815173 for summary.
- Trial name
- NCT05815186
- Testing
- Sotorasib, Ladarixin
- Where
- 6 sites in United States
- Sponsor
- NYU Langone Health
Advanced Solid Tumor
A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors
This is a single-arm, open-label, clinical pharmacology study to evaluate the safety of RNA tumor vaccine injection alone/in combination with PD-1 inhibitor in the treatment of advanced solid tumors with KRAS mutation.
- Trial name
- NCT05202561
- Testing
- RNA tumor vaccine, RNA tumor vaccine+Navuliumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Advanced Cancer, Metastatic Cancer
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
- Trial name
- NCT04330664
- Testing
- MRTX849, TNO155
- Where
- 17 sites in United States
- Volunteers
- 86 people
- Sponsor
- Mirati Therapeutics Inc.
Metastatic Pancreatic Adenocarcinoma, Colorectal Cancer
TCR1020-CD8 T Cells in KRAS-mutated Cancers
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1020-CD8 T cells in patients with KRAS-mutated cancers.
- Trial name
- NCT06707896
- Testing
- TCR1020-CD8 T cells
- Sponsor
- University of Pennsylvania
KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to…
- Conditions
- KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT03608631
- Testing
- Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Non-Small Cell
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based…
- Trial name
- NCT06659042
- Testing
- Tislelizumab, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shanghai Chest Hospital
Advanced Colorectal Cancer, Small Intestinal Cancer
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer，advanced small intestine cancer and advanced…
- Conditions
- Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
- Trial name
- NCT05194995
- Testing
- JAB-21822, Cetuximab
- Where
- 17 sites in China
- Volunteers
- 48 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
- Trial name
- NCT04956640
- Testing
- LY3537982, Pembrolizumab, Cetuximab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 540 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer, CRC
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in…
- Conditions
- Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
- Trial name
- NCT06106308
- Testing
- Onvansertib, FOLFIRI, Bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 110 people
- Sponsor
- Cardiff Oncology
Advanced Solid Tumors
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in…
- Trial name
- NCT07172919
- Testing
- Sotorasib, Panitumumab
- Where
- 11 sites in United States, Australia and 7 more
- Volunteers
- 14 people
- Sponsor
- Amgen
Pancreatic Ductal Adenocarcinoma
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based…
- Trial name
- NCT05630989
- Testing
- combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy with MEKi-EGFRi
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mandana Kamgar, MD
NSCLC Stage IV, KRAS Gene Mutation
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small…
- Conditions
- NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody, Chemotherapy Effect
- Trial name
- NCT03777124
- Testing
- SHR-1210, Apatinib, Pemetrexed
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-Small Cell Lung Cancer
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications
Summary: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the world. This neoplasia has a poor survival prognosis due to the low effectiveness of existing treatments.
- Trial name
- 007/055/OMI (NCT01023828)
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- National Institute of Cancerología
Pancreatic Cancer, Circulating Tumor DNA
CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer
With an incidence of more than 11,600 new cases per year in France and an annual number of deaths close to the incidence rate, adenocarcinoma of the pancreas is a public health problem.
- Conditions
- Pancreatic Cancer, Circulating Tumor DNA, KRAS Mutation-Related Tumors
- Trial name
- NCT04560270
- Testing
- Blood samples
- Volunteers
- 69 people
- Sponsor
- Poitiers University Hospital
Carcinoma, Non-Small Cell Lung
Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer
The purpose of this study is to determine whether carboplatin-paclitaxel-bevacizumab results in a prolonged progression free survival compared to cisplatin-pemetrexed as first line treatment in patients with KRAS mutated…
- Trial name
- NCT02743923
- Testing
- carboplatin, paclitaxel, Bevacizumab
- Where
- 28 sites in Netherlands
- Volunteers
- 203 people
- Sponsor
- The Netherlands Cancer Institute
Cancer, Solid Tumor Cancer
Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor
- Conditions
- Cancer, Solid Tumor Cancer, Biomarkers
- Trial name
- NCT06944457
- Testing
- MPD-1
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Pharosgen Co.,Ltd
Advanced Solid Tumors, Metastatic Solid Tumors
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors…
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
- Trial name
- NCT07397338
- Testing
- Daraxonrasib, Elironrasib, Zoldonrasib
- Where
- 19 sites in United States
- Volunteers
- 370 people
- Sponsor
- Revolution Medicines, Inc.
Non-small Cell Lung Cancer Metastatic
K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation
The goal of this interventional study is to learn about the combination of sotorasib and stereotactic radiation therapy (SBRT) in patients with metastatic non-small cell lung cancer (NSCLC) with KRASG12C mutations.
- Trial name
- K-SAB (NCT06127940)
- Testing
- Stereotactic body radiation therapy (SBRT), Temporary Stopping
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska University Hospital
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
This study aims to evaluate the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C…
- Trial name
- KontRASt-06 (NCT05445843)
- Testing
- JDQ443
- Where
- 45 sites in United States, Argentina and 17 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Pancreatic Cancer
A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT03819387
- Testing
- NBF-006
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Nitto BioPharma, Inc.